Literature DB >> 19552626

Chemokine degradation by the Group A streptococcal serine proteinase ScpC can be reconstituted in vitro and requires two separate domains.

Andrea Fritzer1, Birgit Noiges, Daniela Schweiger, Angelika Rek, Andreas J Kungl, Alexander von Gabain, Eszter Nagy, Andreas L Meinke.   

Abstract

Streptococcus pyogenes is one of the most common human pathogens and possesses diverse mechanisms to evade the human immune defence. One example of its immune evasion is the degradation of the chemokine IL (interleukin)-8 by ScpC, a serine proteinase that prevents the recruitment of neutrophils to an infection site. By applying the ANTIGENome technology and using human serum antibodies, we identified Spy0416, annotated as ScpC, as a prominent antigen that induces protective immune responses in animals. We demonstrate here for the first time that the recombinant form of Spy0416 is capable of IL-8 degradation in vitro in a concentration- and time-dependent manner. Mutations in the conserved amino acid residues of the catalytic triad of Spy0416 completely abolished in vitro activity. However, the isolated predicted proteinase domain does not exhibit IL-8-degrading activity, but is dependent on the presence of the C-terminal region of Spy0416. Binding to IL-8 is mainly mediated by the catalytic domain. However, the C-terminal region modulates substrate binding, indicating that the proteolytic activity is amenable to regulation via the non-catalytic regions. The specificity for human substrates is not restricted to IL-8, since we also detected in vitro protease activity for another CXC chemokine GRO-alpha (growth-related oncogene alpha), but not for NAP-2 (neutrophil-activating protein 2), SDF (stromal-cell-derived factor)-1alpha, PF-4 (platelet factor 4), I-TAC (interferon-gamma-inducible T-cell alpha-chemoattractant), IP-10 (interferon-gamma-inducible protein 10) and MCP-1 (monocyte chemoattractant protein 1). The degradation of two human CXC chemokines in vitro, the high sequence conservation, the immunogenicity of the protein in humans and the shown protection in animal studies suggest that Spy0416 is a promising vaccine candidate for the prevention of infections by S. pyogenes.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19552626     DOI: 10.1042/BJ20090278

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  11 in total

1.  SpyA, a C3-like ADP-ribosyltransferase, contributes to virulence in a mouse subcutaneous model of Streptococcus pyogenes infection.

Authors:  Jessica S Hoff; Mark DeWald; Steve L Moseley; Carleen M Collins; Jovanka M Voyich
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

2.  Novel conserved group A streptococcal proteins identified by the antigenome technology as vaccine candidates for a non-M protein-based vaccine.

Authors:  Andrea Fritzer; Beatrice M Senn; Duc Bui Minh; Markus Hanner; Dieter Gelbmann; Birgit Noiges; Tamás Henics; Kai Schulze; Carlos A Guzman; John Goodacre; Alexander von Gabain; Eszter Nagy; Andreas L Meinke
Journal:  Infect Immun       Date:  2010-07-12       Impact factor: 3.441

3.  MEF2 is regulated by CaMKIIδ2 and a HDAC4-HDAC5 heterodimer in vascular smooth muscle cells.

Authors:  Roman Ginnan; Li Yan Sun; John J Schwarz; Harold A Singer
Journal:  Biochem J       Date:  2012-05-15       Impact factor: 3.857

4.  Streptococcal m1 protein triggers farnesyltransferase-dependent formation of CXC chemokines in alveolar macrophages and neutrophil infiltration of the lungs.

Authors:  Songen Zhang; Milladur Rahman; Su Zhang; Bengt Jeppsson; Heiko Herwald; Henrik Thorlacius
Journal:  Infect Immun       Date:  2012-09-04       Impact factor: 3.441

5.  The CXC chemokine-degrading protease SpyCep of Streptococcus pyogenes promotes its uptake into endothelial cells.

Authors:  Simran Jeet Kaur; Andreas Nerlich; Simone Bergmann; Manfred Rohde; Marcus Fulde; Dorothea Zähner; Emanuel Hanski; Annelies Zinkernagel; Victor Nizet; Gursharan S Chhatwal; Susanne R Talay
Journal:  J Biol Chem       Date:  2010-06-18       Impact factor: 5.157

6.  Chemokine-cleaving Streptococcus pyogenes protease SpyCEP is necessary and sufficient for bacterial dissemination within soft tissues and the respiratory tract.

Authors:  Prathiba Kurupati; Claire E Turner; Ioanna Tziona; Richard A Lawrenson; Faraz M Alam; Mahrokh Nohadani; Gordon W Stamp; Annelies S Zinkernagel; Victor Nizet; Robert J Edwards; Shiranee Sriskandan
Journal:  Mol Microbiol       Date:  2010-02-10       Impact factor: 3.501

7.  Cloning, expression, purification, crystallization and preliminary X-ray diffraction analysis of SpyCEP, a candidate antigen for a vaccine against Streptococcus pyogenes.

Authors:  Francesca Abate; Enrico Malito; Fabiana Falugi; Immaculada Margarit Y Ros; Matthew James Bottomley
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2013-09-28

8.  Structure, dynamics and immunogenicity of a catalytically inactive CXC chemokine-degrading protease SpyCEP from Streptococcus pyogenes.

Authors:  Sophie McKenna; Enrico Malito; Sarah L Rouse; Francesca Abate; Giuliano Bensi; Emiliano Chiarot; Francesca Micoli; Francesca Mancini; Danilo Gomes Moriel; Guido Grandi; Danuta Mossakowska; Max Pearson; Yingqi Xu; James Pease; Shiranee Sriskandan; Immaculada Margarit; Matthew J Bottomley; Stephen Matthews
Journal:  Comput Struct Biotechnol J       Date:  2020-03-13       Impact factor: 7.271

Review 9.  The Role of Streptococcal Cell-Envelope Proteases in Bacterial Evasion of the Innate Immune System.

Authors:  Sophie McKenna; Kristin Krohn Huse; Sean Giblin; Max Pearson; Mohammed Said Majid Al Shibar; Shiranee Sriskandan; Stephen Matthews; James Edward Pease
Journal:  J Innate Immun       Date:  2021-10-14       Impact factor: 7.111

10.  Streptococcus pyogenes SpyCEP influences host-pathogen interactions during infection in a murine air pouch model.

Authors:  Nico Chiappini; Anja Seubert; John L Telford; Guido Grandi; Davide Serruto; Immaculada Margarit; Robert Janulczyk
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.